Discovery paid by milestone
Placement: a judgment drawn from the evidence, open to correction (dispute it).
The model
- Definition
- A platform company designs candidate molecules with AI models and licenses them to pharma partners in deals structured as an upfront fee plus a series of payments released only when specific research and development milestones are hit.
- In one line
- An AI drug discovery platform earns upfront fees plus payments released as each research milestone is hit.
- What compounds
- Each program generates data that sharpens the platform; each milestone hit raises the value of the next deal.
- Who accelerates
- Pharma partners buy optionality on more targets; the platform shares in the upside of what it finds.
- What it displaces
- In-house early discovery and fee-for-service contract research.
- Stops working when
- When candidates fail in the clinic and partners stop renewing. Capital alone is not evidence: Xaira has raised US$1.3 billion with no disclosed partnership revenue.
Evidence
Companies 4
Evidence items 5
Grades 3A 2B
Latest dated 2026-07
Counter-evidence 2
Evidence items 5
Grades 3A 2B
Latest dated 2026-07
Counter-evidence 2
The three labels
2. Rides · loop gain positive. Each step of the curve makes its own loop stronger.
Selling the finished work · money lands in the outcome, not the tool or the hours.
Learning loop · use, data, better product, more use.
Same rung and family
Named companies 4 companies · grade per item
| Company | Claim | Date | Gr | Source |
|---|---|---|---|---|
| Isomorphic Labs United Kingdom · startup · best B |
Deals with Eli Lilly ($45M upfront, up to $1.7B in milestones) and Novartis ($37.5M upfront, up to $1.2B in milestones), combined potential value about $3B | 2024-01-07 | B | Endpoints News |
| Recursion Pharmaceuticals United States · public · best A |
Received a $4M milestone payment from Sanofi in February 2026 (fifth progress-based milestone), bringing cumulative upfront and milestone payments from that partnership to $134M; potential for up to 15 AI-designed small molecule programs | 2026-02-25 | A | Recursion Pharmaceuticals IR |
| Received $213M cumulative upfront and milestone payments from Roche/Genentech collaboration, including a $30M milestone accepted in October 2025 for the second Phenomap | 2026-02-25 | A | Recursion Pharmaceuticals IR | |
| Insilico Medicine Hong Kong / China · public · best A |
2025 total revenue of US$56.24M; over 10 new multinational pharma collaborations signed in 2025 totaling US$1.3B, taking cumulative collaboration value to US$4.6B; listed on Hong Kong Main Board 2025-12-30 in what was described as Hong Kong's largest biotech IPO of the year | 2026-03-29 | A | Insilico Medicine |
| Xaira TherapeuticsCOUNTER United States · startup · best B |
Raised $1.3B to date; as of a July 2026 profile, has no publicly announced revenue-generating pharma partnerships and is only now (since hiring a business-development SVP in March 2026) starting to seek data-partnership deals, not capital | 2026-07 | B | BioSpace |
Counter-evidence Reversals, failures and disputes
| Xaira Therapeutics, one of the best-funded AI drug discovery platforms ($1.3B raised), has disclosed no partnership revenue as of mid-2026, illustrating that even well-capitalized AI-first biotechs can take years before landing milestone deals | 2026-07 | BioSpace |
| Xaira Therapeutics is listed above as a counter-example. |
Sources 4
Endpoints News endpoints.news · 2024-01-07
Recursion Pharmaceuticals IR ir.recursion.com · 2026-02-25
Insilico Medicine insilico.com · 2026-03-29
BioSpace biospace.com · 2026-07
Recursion Pharmaceuticals IR ir.recursion.com · 2026-02-25
Insilico Medicine insilico.com · 2026-03-29
BioSpace biospace.com · 2026-07